Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestogen presented as a 52 mg intrauterine system for intrauterine use. It provides long‑term contraception and can be used to manage heavy menstrual bleeding and endometriosis‑related pain in women of reproductive age.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirena, a levonorgestrel‑releasing intrauterine system, is indicated for conditions that benefit from local progestogenic activity.

- Long‑term contraception: provides up to five years of highly effective birth control for women of reproductive age. - Heavy menstrual bleeding: markedly reduces menstrual blood loss and helps correct anemia associated with excessive bleeding. - Endometriosis‑related pain: alleviates chronic pelvic pain caused by endometriotic lesions through local hormonal suppression.

Common Side Effects: - Irregular vaginal bleeding or spotting, especially during the first months of use. - Amenorrhea (absence of periods) after prolonged use. - Cramping or pelvic discomfort after insertion. - Ovarian cyst formation, usually benign and self‑limiting. - Breast tenderness or mild breast enlargement. - Mood changes, including mild depression or anxiety.

Serious or Rare Side Effects: - Uterine perforation during insertion, requiring surgical management. - Expulsion of the device, which can reduce contraceptive efficacy. - Pelvic inflammatory disease or severe infection of the uterus. - Ectopic pregnancy if contraception fails. - Severe allergic reaction (anaphylaxis) to levonorgestrel or device components. - Deep vein thrombosis or other thromboembolic events, though rare.

Before insertion, clinicians should evaluate patient history and counsel on potential risks.

- Screen for pregnancy: confirm the patient is not pregnant prior to placement. - Assess uterine anatomy: use ultrasound to verify a normal uterine cavity and position. - Monitor for infection: advise patients to seek immediate care for fever, pelvic pain, or abnormal discharge. - Review concurrent medications: avoid enzyme‑inducing drugs that may lower levonorgestrel effectiveness. - Counsel on bleeding changes: inform patients that irregular bleeding or amenorrhea are common. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Mirena may interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy. - Rifampicin or other strong rifamycins: can lower levonorgestrel levels. - Certain antiretroviral protease inhibitors: potential alteration of hormone activity.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase levonorgestrel exposure. - St. John’s wort: may diminish contraceptive effectiveness. - Some antibiotics (e.g., tetracycline): limited evidence of impact, monitor bleeding patterns.